Log in

NASDAQ:CDXC - Chromadex Stock Price, Forecast & News

$4.10
-0.04 (-0.97 %)
(As of 02/17/2020 02:43 AM ET)
Add
Today's Range
$4.06
Now: $4.10
$4.16
50-Day Range
$4.01
MA: $4.33
$4.75
52-Week Range
$2.68
Now: $4.10
$4.95
Volume129,729 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:CDXC
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees100
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive CDXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.


Chromadex (NASDAQ:CDXC) Frequently Asked Questions

What is Chromadex's stock symbol?

Chromadex trades on the NASDAQ under the ticker symbol "CDXC."

How were Chromadex's earnings last quarter?

Chromadex Corp (NASDAQ:CDXC) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.12) EPS for the quarter, meeting analysts' consensus estimates of ($0.12). The firm earned $12.05 million during the quarter, compared to analyst estimates of $11.66 million. View Chromadex's Earnings History.

When is Chromadex's next earnings date?

Chromadex is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Chromadex.

What price target have analysts set for CDXC?

3 Wall Street analysts have issued 1 year target prices for Chromadex's shares. Their forecasts range from $6.00 to $6.00. On average, they expect Chromadex's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 46.3% from the stock's current price. View Analyst Price Targets for Chromadex.

What is the consensus analysts' recommendation for Chromadex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chromadex.

What are Wall Street analysts saying about Chromadex stock?

Here are some recent quotes from research analysts about Chromadex stock:
  • 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (1/15/2020)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We apply a 26.6x EV-to-EBITDA multiple applied to our 2020 EBITDA per share estimate of $0.35, discounted back at a 12% rate, which yields a price objective of approximately $7.00 per share." (4/25/2019)

Has Chromadex been receiving favorable news coverage?

News headlines about CDXC stock have trended somewhat positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chromadex earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Chromadex.

What other stocks do shareholders of Chromadex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chromadex investors own include Tilray (TLRY), Heron Therapeutics (HRTX), TransEnterix (TRXC), Athersys (ATHX), Glu Mobile (GLUU), Axsome Therapeutics (AXSM), CELYAD SA/ADR (CYAD), Mesoblast (MESO), Sorrento Therapeutics (SRNE) and Nabriva Therapeutics (NBRV).

Who are Chromadex's key executives?

Chromadex's management team includes the folowing people:
  • Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 51)
  • Mr. Robert N. Fried, CEO & Director (Age 59)
  • Mr. Kevin M. Farr, Chief Financial Officer (Age 61)
  • Mr. Ben Shichman, Chief Technology Officer
  • Dr. Matthew Roberts, Chief Scientific Officer & Sr. VP of Innovation

Who are Chromadex's major shareholders?

Chromadex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Tieton Capital Management LLC (2.60%), State Street Corp (1.15%), Mercator Fund Cayman Master LP (0.53%), UBS Group AG (0.40%), Bank of New York Mellon Corp (0.22%) and Charles Schwab Investment Management Inc. (0.17%). Company insiders that own Chromadex stock include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, Robert N Fried and Stephen A Block. View Institutional Ownership Trends for Chromadex.

Which major investors are selling Chromadex stock?

CDXC stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, New York State Common Retirement Fund and Bank of America Corp DE. View Insider Buying and Selling for Chromadex.

Which major investors are buying Chromadex stock?

CDXC stock was acquired by a variety of institutional investors in the last quarter, including Mercator Fund Cayman Master LP, Tieton Capital Management LLC, State Street Corp, California Public Employees Retirement System, UBS Group AG, Barclays PLC, Resources Investment Advisors LLC. and Insight 2811 Inc.. Company insiders that have bought Chromadex stock in the last two years include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman and Robert N Fried. View Insider Buying and Selling for Chromadex.

How do I buy shares of Chromadex?

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Chromadex's stock price today?

One share of CDXC stock can currently be purchased for approximately $4.10.


MarketBeat Community Rating for Chromadex (NASDAQ CDXC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  459 (Vote Outperform)
Underperform Votes:  516 (Vote Underperform)
Total Votes:  975
MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Cost of Goods Sold (COGS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel